



Reveal more with the illuminating power of CTCs

Shine a new light on cancer cells with the combined power of the
Portrait[®]+ CTC staining kit and Parsortix[®] technology

Authorized Distribution Partners:

USA address: 9494 Southwest FWY Suite Houston, Texas 77407.

Phone: +17134018533

Pakistan Address: Lower Ground, 71—C, Jami Commercial, Street no 9, Phase VII, DHA, Karachi
City.

Phone: +923313670913

email us at: contact@biosmdpharma.com

website: <https://biosmdpharma.com/>

angleplc.com



Identify circulating tumor cells (CTCs) with the Portrait®+ CTC staining kit and Parsortix® technology

Portrait+ CTC staining kit

- Provides advanced immunofluorescent staining of CTCs enriched from blood by Parsortix technology.
- Enables the identification and enumeration of epithelial and mesenchymal cells including those undergoing epithelial-to-mesenchymal transition (EMT).
- EMT is a key transition step in cancer cells, and is associated with tumor progression, the development of drug resistance, and metastasis.¹⁻³

Discover a new level of clarity

The Portrait+ CTC staining kit uses direct staining and an optimized, vivid dye combination, to ensure high signal intensity while maintaining high analytical specificity and sensitivity (figure 1).

- Visualize CTCs from multiple cancer types, including ovarian, breast, lung and prostate.
- Provides insights to help you make more informed decisions about further downstream analysis.

Easy to use, reliable results

Antibodies are supplied pre-mixed and lyophilized for ease-of-use and long-term storage.

- Have confidence with consistent, reliable results from fully-validated, standardized protocols.
- Provides an alternative to costly and time-consuming in-cassette staining.

Efficiency without compromise

The Portrait+ CTC staining kit includes the CellKeep™ slide, a unique CTC harvesting technology to maximize the retention of CTCs enriched from blood samples.

- Confines the harvested CTCs to a small area, reducing the volume of antibodies required for staining and decreasing imaging time.
- Helps drive process efficiency and minimize cost.


Powered by Parsortix

The Portrait+ CTC staining kit is optimized to work with ANGLE's unique Parsortix technology.

- Trusted technology, with over 90 publications.
- Parsortix technology uses antibody-independent methodology to capture epithelial, mesenchymal and EMT CTCs, and CTC clusters from whole blood samples.



Example images from patient blood samples




Key

White - white blood cell marker (Cy5)
Blue - nucleus (DAPI)

Red - mesenchymal marker (Cy3)
Green - epithelial marker (FITC)

Examples of Portrait+ CTC staining kit samples



Healthy volunteer blood samples spiked with SKBR3 and Hs 578T cancer cell lines.

Key

White - white blood cell marker (Cy5)
Blue - nucleus (DAPI)

Red - mesenchymal marker (Cy3)
Green - epithelial marker (FITC)

Portrait+ CTC staining kit analytical sensitivity and analytical specificity*




Figure 1.

Key performance metrics using Hs 578T (mesenchymal) and SKBR3 (epithelial) cell lines spiked and recovered from peripheral blood using Parsortix technology. Mean analytical sensitivity and analytical specificity.

Ordering Information

Product name: Portrait+ CTC staining kit

Product code: POR-AK-010

Kit contains:

10 × CellKeep slides	1 × Vial containing 100 µL of reconstitution buffer
1 × Slide detacher	1 × Vial of antibody formulation (lyophilized), sufficient for staining of 10 slides
20 × Wicking caps	

Authorized Distribution Partners:

USA address: 9494 Southwest FWY Suite Houston, Texas 77407.

Phone: +17134018533

Pakistan Address: Lower Ground, 71—C, Jami Commercial, Street no 9, Phase VII, DHA, Karachi City.

Phone: +923313670913

email us at: contact@biosmdpharma.com

website: <https://biosmdpharma.com/>

References:

1. Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. *Annu. Rev. Pathol.* 13, 395–412 (2018).
2. Silvestri, M. et al. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. *Sci. Rep.* 12, 1470 (2022).
3. Payne, K. et al. Characterizing the epithelial–mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma. *Head Neck* 44, 2545–2554 (2022).